Neurotronic
1 known investors
Neurotronic is developing Neuviant Multi-organ Denervation (MDN), an investigational catheter-based therapy that delivers ethanol to overactive sympathetic nerves near the kidneys and liver to lower blood sugar and blood pressure. It targets patients with type 2 diabetes and hypertension that remain uncontrolled despite lifestyle changes and medication, and is being evaluated in the U.S. TRIUMPH clinical study.</parameter> <parameter name="sector_codes">["medtech", "healthtech", "biotech"]